A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs DOI Creative Commons

Jianzhu Xie,

Binjie Hu,

Yanping Gong

et al.

Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Dec. 1, 2023

Abstract Background Liquid biopsy provides a non-invasive approach that enables detecting circulating tumor DNA (ctDNA) and cells (CTCs) using blood specimens theoretically benefits early finding primary or monitoring treatment response as well recurrence. Despite many studies on these novel biomarkers, their clinical relevance remains controversial. This study aims to investigate the correlation between ctDNA, CTCs, tumor-derived endothelial (CTECs) while also evaluating whether mutation profiling in ctDNA is consistent with tissue from lung cancer patients. These findings will help evaluation utilization of approaches practice. Methods 104 participants (49 31 benign lesions) underwent CTCs CTECs detection integrating subtraction enrichment immunostaining-fluorescence situ hybridization (SE-iFISH) strategy. The cell-free (cfDNA) concentration was measured mutational profiles were examined by Roche AVENIO Expanded Kit (targeted total 77 genes) next generation sequencing (NGS) 28 patients (20 8 highest numbers CTECs. Mutation validation matched then performed 9 mutations customized xGen pan-solid kit 474 NGS. Results sensitivity specificity number for diagnosis NSCLC 67.3% 77.6% [AUC (95%CI): 0.815 (0.722–0.907)], 83.9% 77.4% 0.739 (0.618–0.860)]. cfDNA plasma statistically correlated size (r = 0.430, P 0.022) CYFRA 21–1 0.411, 0.041), but not In this study, found be poorly (tDNA) patients, even when numerous present. Conclusion Detection could potential adjunct tool cancer. levels are associated burden, rather than counts. Moreover, tDNA require further exploration.

Language: Английский

Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment DOI
Alessandro Russo, Jessica Lee, Lincoln W. Pasquina

et al.

JCO Precision Oncology, Journal Year: 2024, Volume and Issue: 8

Published: Jan. 31, 2024

Studies have investigated the early use of liquid biopsy (LBx) during diagnostic workup patients presenting with clinical evidence advanced lung cancer, but real-world adoption and impact has not been characterized. The aim this study was to determine whether LBx before diagnosis (Dx; LBx-Dx) enables timely comprehensive genomic profiling (CGP) shortens time until treatment initiation for non-small-cell cancer (aNSCLC).

Language: Английский

Citations

11
Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review DOI Open Access
Juan Carlos Restrepo,

Darly Martínez Guevara,

Andrés Pareja López

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(13), P. 2338 - 2338

Published: June 26, 2024

Non-small-cell lung cancer (NSCLC) comprises approximately 85% of all cases, often diagnosed at advanced stages, which diminishes the effective treatment options and survival rates. This systematic review assesses utility emerging biomarkers-circulating tumor DNA (ctDNA), microRNAs (miRNAs), blood mutational burden (bTMB)-enhanced by next-generation sequencing (NGS) to improve diagnostic accuracy, prognostic evaluation, strategies in NSCLC. Analyzing data from 37 studies involving 10,332 patients 2020 2024, highlights how biomarkers like ctDNA PD-L1 expression critically inform selection personalized therapies, particularly beneficial stages These are critical for assessments dynamically adapting plans, where high specific genetic mutations (e.g., ALK fusions, EGFR mutations) significantly guide use targeted therapies immunotherapies. The findings recommend integrating these into standardized clinical pathways maximize their potential enhancing precision, ultimately fostering significant advancements oncology improving patient outcomes quality life. substantiates predictive value emphasizes need ongoing innovation biomarker research.

Language: Английский

Citations

9
What the clinician needs to know about laboratory analyses of circulating tumor DNA DOI

Cecilie Mondrup Jacobsen,

Luísa Matos do Canto,

Søren Kahns

et al.

Clinical Colorectal Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

1
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology DOI Creative Commons
Alexandra Bartolomucci, Monyse de Nóbrega,

Tadhg Ferrier

et al.

npj Precision Oncology, Journal Year: 2025, Volume and Issue: 9(1)

Published: March 24, 2025

Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker in cancer, evidenced by its increasing integration into clinical practice. Carrying specific characteristics, ctDNA can be used to inform treatment selection, monitor response, and identify drug resistance. In this review, we provide comprehensive, up-to-date summary of monitoring response with focus on lung, colorectal, breast cancers, discuss current challenges future directions.

Language: Английский

Citations

1
Circulating tumor DNA as liquid biopsy in lung cancer: Biological characteristics and clinical integration DOI Creative Commons
Changshu Li, Jun Shao, Peiyi Li

et al.

Cancer Letters, Journal Year: 2023, Volume and Issue: 577, P. 216365 - 216365

Published: Aug. 25, 2023

Lung cancer maintains high morbidity and mortality rate globally despite significant advancements in diagnosis treatment the era of precision medicine. Pathological analysis tumor tissue, current gold standard for lung diagnosis, is intrusive intrinsically confined to evaluating limited amount tissues that could be physically extracted. However, tissue biopsy has several limitations, including invasiveness procedure difficulty obtaining samples patients at advanced stages., there Additionally,has been no major breakthrough biomarkers with specificity sensitivity, particularly early-stage cancer. Liquid considered a feasible auxiliary tool tearly dianosis, responses monitoring prognosis Circulating DNA (ctDNA), an ideal biomarker liquid biopsy, emerged as one most reliable tools processes molecular levels. Herein, this review focuses on heterogeneity elucidate superiority retrospectively discussdeciphersolution. We systematically elaborate ctDNA biological characteristics, introduce methods detection, discuss role plasma management. Finally, we summarize drawbacks highlight its potential clinical application

Language: Английский

Citations

16
Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications DOI Open Access
Margo B. Gerke,

Caroline S. Jansen,

Mehmet Asim Bilen

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(12), P. 2280 - 2280

Published: June 20, 2024

CtDNA is emerging as a non-invasive clinical detection method for several cancers, including genitourinary (GU) cancers such prostate cancer, bladder and renal cell carcinoma (RCC). assays have shown promise in early of GU providing prognostic information, assessing real-time treatment response, detecting residual disease relapse. The ease obtaining “liquid biopsy” from blood or urine enhances its potential to be used biomarker. Interrogating these biopsies” ctDNA can then detect common cancer mutations, novel genomic alterations, epigenetic modifications. has undergone investigation numerous trials, which could address needs instance, earlier RCC, therapeutic response prediction castration-resistant monitoring recurrence cancers. utilization liquid biopsy analysis provides promising advancing precision medicine within the field

Language: Английский

Citations

4
Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions DOI
Ana Gloria Badani, Ahmad Ozair, Mustafa Khasraw

et al.

Journal of Neuro-Oncology, Journal Year: 2024, Volume and Issue: 171(3), P. 531 - 547

Published: Nov. 21, 2024

Language: Английский

Citations

4
The Current Role of Circulating Tumor DNA in the Management of Pancreatic Cancer DOI Creative Commons
M.C. Cox, Dominic Vitello,

Akhil Chawla

et al.

Journal of Gastrointestinal Cancer, Journal Year: 2025, Volume and Issue: 56(1)

Published: Jan. 14, 2025

Language: Английский

Citations

0
Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study) DOI Creative Commons
Ramy Samaha, Rola El Sayed, Raafat Alameddine

et al.

Current Oncology, Journal Year: 2025, Volume and Issue: 32(2), P. 57 - 57

Published: Jan. 21, 2025

Background: Lung cancer remains the leading cause of mortality globally with EGFR mutations representing a significant driver in advanced non-small cell lung (aNSCLC). The timely detection these is critical for initiating targeted therapy, yet tissue biopsy limitations often delay treatment. Methods: This multicenter prospective study evaluated clinical utility liquid (LBx) real-life settings early diagnosis patients suspected aNSCLC. Circulating tumor DNA (ctDNA) was analyzed using Cobas Mutation Test and compared to tissue-based next-generation sequencing (NGS). Results: Among 366 aNSCLC tested, LBx demonstrated significantly shorter median turnaround time (TAT) 3 days 26 NGS (p < 0.001) 100% specificity 65% sensitivity mutation detection. identified actionable cases where insufficient or unavailable, enabling 43.7% commence therapy based on ctDNA results prior confirmation. Conclusions: These findings highlight potential reduce diagnostic delays improve access personalized therapies real-world setting. Integrating into routine workflows may address current gaps molecular testing, ensuring precise treatment patients.

Language: Английский

Citations

0
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non–Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02 DOI

Zhenhao Qi,

Shinya Tokuhiro,

Justin I. Odegaard

et al.

Journal of Molecular Diagnostics, Journal Year: 2025, Volume and Issue: 27(2), P. 119 - 129

Published: Jan. 27, 2025

Language: Английский

Citations

0